To test if CDK4/6 inhibition combined with MET inhibition is a feasible strategy for cancer treatment in vivo, we assessed the combined effect of crizotinib and palbociclib on the growth of human tumour xenografts in athymic mice. The gene discussed is MET; the disease is neoplasm.